Similar to the previous study involving the use of an anti-PD-1 antibody of murine origin, the combination of Nexavant and nivolumab was found to be more effective than the respective monotherapies in both the B16F10 melanoma and the EMT6 TNBC models (Figure 6A,B, respectively). This evidence concerns the gene PDCD1 and melanoma.